Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Stephen D. Wiviott, M.D., Eugene Braunwald, M.D., Carolyn H. McCabe, B.S., Gilles Montalescot, M.D., Ph.D., Witold Ruzyllo, M.D., Shmuel Gottlieb, M.D., Franz-Joseph Neumann, M.D., Diego Ardissino, M.D., Stefano De Servi, M.D., Sabina A. Murphy, M.P.H., Jeffrey Riesmeyer, M.D., Govinda Weerakkody, Ph.D., C. Michael Gibson, M.D., Elliott M. Antman, M.D., for the TRITON–TIMI 38 Investigators
Background Dual-antiplatelet therapy with aspirin and a thienopyridineis a cornerstone of treatment to prevent thrombotic complicationsof acute coronary syndromes and percutaneous coronary intervention.
Methods To compare prasugrel, a new thienopyridine, with clopidogrel,we randomly assigned 13,608 patients with moderate-to-high-riskacute coronary syndromes with scheduled percutaneous coronaryintervention to receive prasugrel (a 60-mg loading dose anda 10-mg daily maintenance dose) or clopidogrel (a 300-mg loadingdose and a 75-mg daily maintenance dose), for 6 to 15 months.The primary efficacy end point was death from cardiovascularcauses, nonfatal myocardial infarction, or nonfatal stroke.The key safety end point was major bleeding.
Results The primary efficacy end point occurred in 12.1% ofpatients receiving clopidogrel and 9.9% of patients receivingprasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81;95% confidence interval [CI], 0.73 to 0.90; P<0.001). Wealso found significant reductions in the prasugrel group inthe rates of myocardial infarction (9.7% for clopidogrel vs.7.4% for prasugrel; P<0.001), urgent target-vessel revascularization(3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs.1.1%; P<0.001). Major bleeding was observed in 2.4% of patientsreceiving prasugrel and in 1.8% of patients receiving clopidogrel(hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greaterin the prasugrel group was the rate of life-threatening bleeding(1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs.0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs.0.1%; P=0.002).
Conclusions In patients with acute coronary syndromes with scheduledpercutaneous coronary intervention, prasugrel therapy was associatedwith significantly reduced rates of ischemic events, includingstent thrombosis, but with an increased risk of major bleeding,including fatal bleeding. Overall mortality did not differ significantlybetween treatment groups. (ClinicalTrials.gov number, NCT00097591
[ClinicalTrials.gov]
.)
Source Information
From Brigham and Women's Hospital and Harvard Medical School, Boston (S.D.W., E.B., C.H.M., S.A.M., C.M.G., E.M.A.); Institut de Cardiologie and INSERM Unit 856, Pitié–Salpêtrière University Hospital, Paris (G.M.); Instytut Kardiologii, Warsaw, Poland (W.R.); Bikur Cholim Hospital, Jerusalem, Israel (S.G.); Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany (F.-J.N.); Azienda Ospedaliero–Universitaria di Parma, Parma, Italy (D.A.); Azienda Ospedaliera Civile di Legano, Legano, Italy (S.D.S.); and Eli Lilly Research Laboratories, Indianapolis (J.R., G.W.). This article (10.1056/NEJMoa0706482) was published at www.nejm.org on November 4, 2007.
Address reprint requests to Dr. Antman at the Cardiovascular Division, Brigham and Women's Hospital, TIMI Study Group, 350 Longwood Ave., 1st Fl., Boston, MA 02115, or at eantman{at}rics.bwh.harvard.edu.
Prasugrel versus Clopidogrel
Serebruany V., Pasceri V., Patti G., Di Sciascio G., von Lewinski F., Riggert J., Paulus W., Wiviott S. D., Braunwald E., Antman E. M., Bhatt D. L.
Extract |
Full Text |
PDF
N Engl J Med 2008;
358:1298-1301, Mar 20, 2008.
Correspondence
This article has been cited by other articles:
Cairns, J. A., Eikelboom, J.
(2008). Clopidogrel Resistance: More Grist for the Mill. J Am Coll Cardiol
51: 1935-1937
[Full Text]
Pocock, S. J., Lubsen, J., Wang, R., Lagakos, S. W.
(2008). More on Subgroup Analyses in Clinical Trials. NEJM
358: 2076-2077
[Full Text]
Wallentin, L.
(2008). Dual antiplatelet therapy in the drug-eluting stent era. Eur Heart J Suppl
10: D38-D44
[Abstract][Full Text]
Valgimigli, M., Campo, G., Percoco, G., Bolognese, L., Vassanelli, C., Colangelo, S., de Cesare, N., Rodriguez, A. E., Ferrario, M., Moreno, R., Piva, T., Sheiban, I., Pasquetto, G., Prati, F., Nazzaro, M. S., Parrinello, G., Ferrari, R., for the Multicentre Evaluation of Single High-Dose,
(2008). Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial. JAMA
299: 1788-1799
[Abstract][Full Text]
Kleiman, N. S.
(2008). Will Measuring Vasodilator-Stimulated Phosphoprotein Phosphorylation Help Us Optimize the Loading Dose of Clopidogrel?. J Am Coll Cardiol
51: 1412-1414
[Full Text]
Kereiakes, D. J., Gurbel, P. A.
(2008). Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention. J Am Coll Cardiol Intv
1: 111-121
[Abstract][Full Text]
Serebruany, V., Pasceri, V., Patti, G., Di Sciascio, G., von Lewinski, F., Riggert, J., Paulus, W., Wiviott, S. D., Braunwald, E., Antman, E. M., Bhatt, D. L.
(2008). Prasugrel versus clopidogrel.. NEJM
358: 1298-1299
[Full Text]
Sanz, J., Moreno, P. R., Fuster, V.
(2008). The year in atherothrombosis.. J Am Coll Cardiol
51: 944-955
[Full Text]
FitzGerald, G. A.
(2008). Summary. Arterioscler. Thromb. Vasc. Bio.
28: s51-s52
[Full Text]
Michelson, A. D.
(2008). P2Y12 Antagonism: Promises and Challenges. Arterioscler. Thromb. Vasc. Bio.
28: s33-s38
[Abstract][Full Text]
Hylek, E. M., Solarz, D. E.
(2008). Dual Antiplatelet and Oral Anticoagulant Therapy: Increasing Use and Precautions for a Hazardous Combination. J Am Coll Cardiol Intv
1: 62-64
[Full Text]
Wallentin, L., Varenhorst, C., James, S., Erlinge, D., Braun, O. O, Jakubowski, J. A., Sugidachi, A., Winters, K. J., Siegbahn, A.
(2008). Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J
29: 21-30
[Abstract][Full Text]
Gitt, A. K., Betriu, A.
(2008). Antiplatelet therapy in acute coronary syndromes. Eur Heart J Suppl
10: A4-A12
[Abstract][Full Text]
Bode, C., Huber, K.
(2008). Antiplatelet therapy in percutaneous coronary intervention. Eur Heart J Suppl
10: A13-A20
[Abstract][Full Text]
Bertrand, M. E.
(2008). When and how to discontinue antiplatelet therapy. Eur Heart J Suppl
10: A35-A41
[Abstract][Full Text]
Wiviott, S. D., Trenk, D., Frelinger, A. L., O'Donoghue, M., Neumann, F.-J., Michelson, A. D., Angiolillo, D. J., Hod, H., Montalescot, G., Miller, D. L., Jakubowski, J. A., Cairns, R., Murphy, S. A., McCabe, C. H., Antman, E. M., Braunwald, E., for the PRINCIPLE-TIMI 44 Investigators,
(2007). Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial. Circulation
116: 2923-2932
[Abstract][Full Text]
Berger, P. B., Manoukian, S. V.
(2007). Bleeding Is Bad.... Isn't It?. Circulation
116: 2776-2778
[Full Text]
(2007). Prasugrel in Patients with Acute Coronary Syndromes. JWatch Oncology and Hematology
2007: 1-1
[Full Text]
Bhatt, D. L.
(2007). Intensifying Platelet Inhibition -- Navigating between Scylla and Charybdis. NEJM
357: 2078-2081
[Full Text]
Previous
